Kazia Therapeutics Ltd ADR - Asset Resilience Ratio
Kazia Therapeutics Ltd ADR (KZIA) has an Asset Resilience Ratio of 0.00% as of December 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See KZIA current assets to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2006–2019)
This chart shows how Kazia Therapeutics Ltd ADR's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see how large is Kazia Therapeutics Ltd ADR's balance sheet.
Liquid Assets Composition Over Time
This chart breaks down Kazia Therapeutics Ltd ADR's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore KZIA strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Kazia Therapeutics Ltd ADR maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Kazia Therapeutics Ltd ADR Industry Peers by Asset Resilience Ratio
Compare Kazia Therapeutics Ltd ADR's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
ALK-Abelló A/S
CO:ALK-B |
Biotechnology | 0.98% |
|
Mirum Pharmaceuticals Inc
NASDAQ:MIRM |
Biotechnology | 6.89% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
BB Biotech AG
SW:BION |
Biotechnology | 92.97% |
|
Soleno Therapeutics Inc
NASDAQ:SLNO |
Biotechnology | 20.15% |
|
Nanobiotix
NASDAQ:NBTX |
Biotechnology | 4.71% |
|
Wuhan Keqian Biology Co Ltd
SHG:688526 |
Biotechnology | 19.42% |
|
Beijing Konruns Pharmaceutical Co Ltd
SHG:603590 |
Biotechnology | 10.55% |
Annual Asset Resilience Ratio for Kazia Therapeutics Ltd ADR (2006–2019)
The table below shows the annual Asset Resilience Ratio data for Kazia Therapeutics Ltd ADR.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2019-06-30 | 0.00% | $0.00 | $21.18 Million | -- |
| 2018-06-30 | 0.00% | $0.00 | $28.18 Million | -- |
| 2017-06-30 | 0.00% | $0.00 | $35.91 Million | -- |
| 2016-06-30 | 0.00% | $0.00 | $35.52 Million | -- |
| 2015-06-30 | 0.00% | $0.00 | $46.14 Million | -- |
| 2014-06-30 | 0.00% | $0.00 | $4.66 Million | -- |
| 2012-06-30 | 2.85% | $256.00K | $8.98 Million | +0.74pp |
| 2011-06-30 | 2.11% | $268.00K | $12.73 Million | -2.29pp |
| 2010-06-30 | 4.40% | $848.00K | $19.29 Million | +2.27pp |
| 2009-06-30 | 2.13% | $806.00K | $37.84 Million | -12.56pp |
| 2008-06-30 | 14.69% | $6.37 Million | $43.38 Million | -3.16pp |
| 2006-06-30 | 17.85% | $9.13 Million | $51.11 Million | -- |
About Kazia Therapeutics Ltd ADR
Kazia Therapeutics Limited, together with its subsidiaries, operates as an oncology-focused biotechnology company in Israel. The company's lead development candidate is paxalisib, a small molecule, brain-penetrant inhibitor of the phosphoinositide-3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway, which is in Phase II/III clinical trial for the treatment of glioblastoma; in Phase I… Read more